Response-adapted therapy (tx) with nivolumab plus brentuximab vedotin (nivo + BV) without autologous hematopoietic cell transplantation (auto-HCT) in children, adolescents, and young adults (CAYA) with low-risk relapsed/refractory (R/R) classic Hodgkin lymphoma (cHL): CheckMate 744

Bibliographic Details
Published in:Journal of Clinical Oncology Vol. 41; pp. 7515 - 7516
Main Authors: Harker-Murray, Paul David, Cole, Peter D., Hoppe, Bradford S., Hodgson, David C., Beishuizen, Auke, Garnier, Nathalie, Buffardi, Salvatore, Mascarin, Maurizio, Lissat, Andrej, Akyol, Alev, Crowe, Russell, Li, Ju, Drachtman, Richard A., Kelly, Kara M, Leblanc, Thierry, Daw, Stephen
Format: Journal Article
Published: American Society of Clinical Oncology 2023 Supplement 16
Online Access:View this record in EBSCOhost